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Abstract Acromegaly is a rare, chronic, and debilitating
disease that results from excessive growth hormone pro-
duction. Clinically, this disease is associated with enlarge-
ment of soft tissue, excessive skeletal growth, and increased
risk of cardiovascular disease. Acromegaly is often diag-
nosed late, when a wide range of comorbidities may already
be present. First-line therapy for acromegaly is typically
surgery; but a number of highly-specific pharmacological
agents have recently enabled a more aggressive medical
management of acromegaly. Since surgical cure of acro-
megaly is low for macroadenomas, medical control of active
acromegaly is an important component of treatment. There
are no published US data currently available regarding real-
world rates of comorbidities and treatment patterns among
patients with acromegaly. This retrospective study examined
the comorbidities and treatment patterns of 949 health plan
enrollees, who had acromegaly diagnosis and/or procedure
codes in an administrative claims database from July 1, 2002
through June 30, 2010. Acromegaly was associated with
high rates of hypertension and diabetes along with a number
of other comorbidities. The incidence of comorbidities was
highest among patients with acromegaly-related treatment,
which may have resulted, in part, from inadequate disease
management and/or poor disease control. Unexpectedly,
55 % of patients identified with acromegaly received no
treatment for acromegaly (i.e., surgery, radiotherapy, and
medication) and only 28 % received a medication treatment
during the observation period. However, some patients may
have received a curative surgery prior to the observation
period, which may have reduced the use of other acromeg-
aly-related treatments during the study period. Of those
treated with medications, the most common first medications
were octreotide, cabergoline, and bromocriptine. Given the
high incidence of serious comorbidities associated with
active acromegaly, earlier diagnosis and treatment, along
with appropriate follow-up care, may potentially avoid the
life-long consequences of uncontrolled disease.
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Introduction
Acromegaly is a debilitating disorder caused by the chronic
hypersecretion of growth hormone (GH). The most frequent
source of excessive GH is a benign pituitary adenoma, which
progresses slowly and may remain undetected for up to
10 years [1]. The risk of morbidity and mortality increases as
the tumor size grows and GH hypersecretion continues [2, 3].
Patients often present with arrhythmias, hypertension, and
valvular heart disease by the time of acromegaly diagnosis [4].
Acromegaly treatments aim to reduce or control tumor
growth, decrease GH levels, and normalize insulin-like growth
factor 1 (IGF-1) concentrations, a hormone stimulated by GH
production [5]. Certain clinical manifestations of acromegaly
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can be reversed or slowed with treatment [1, 2, 5–7]. Some
reversible conditions include carpal tunnel syndrome, sweat-
ing, and obstructive sleep apnea, but others such as diabetes,
hypertension, and heart disease may remain the same or only
show slight improvement with acromegaly treatment [8]. By
correcting the overproduction of GH and IGF-1, a recent meta-
analysis suggests that the mortality for treated acromegaly
patients was nearly equivalent to the mortality expected of the
general population [9].
The primary treatment for acromegaly is tumor excision
via transsphenoidal surgery. At diagnosis, more than 75 % of
acromegaly patients have a macroadenoma ([10 mm in
diameter) but\50 % of macroadenomas are controlled with
surgery alone [4, 6]. Among acromegaly patients with a
microadenoma, surgery is more than 80 % effective at
lowering GH and normalizing IGF-1 [4]. Post-operative
treatments consist of medical therapy and radiotherapy.
Medical therapy for acromegaly includes medications in
three drug classes: injectable somatostatin analogs [octreo-
tide acetate, octreotide long-acting release (LAR), and lan-
reotide]; injectable GH receptor antagonist (pegvisomant);
and oral dopamine agonists (bromocriptine and cabergo-
line). Medical therapy may be given as a first-line therapy
when surgery is too dangerous or unlikely to cure or as a
second-line therapy if the tumor recurred or surgery failed to
achieve biochemical control [5]. Up to 10 % of removed
tumors recur [4]. Radiotherapy is often given as a third-line
therapy to patients unable to withstand medical therapy or as
a second-line therapy to patients with a tumor inaccessible
through surgery. However, radiotherapy is not as safe as
some of the other therapy options. For patients receiving new
or conventional radiotherapy, more than 50 % are at risk of
hypopituitarism, and nearly 6 % are at risk of vision defects
[5]. Secondary tumors and cerebrovascular events are also a
potential risk with conventional radiotherapy.
Acromegaly is a rare condition with an estimated annual
incidence of only 3.3 cases per million and a prevalence
ranging from 40 to 130 per million [6, 10]. Data on the burden
of illness for acromegaly patients are limited, and there are
no published US data currently available. The goal of this
study was to examine real-world comorbidities and treat-
ment of acromegaly patients in US commercial health plans.
Methods
Study design
This retrospective study analyzed administrative claims
from two large commercial health plan databases from July
1, 2002 through June 30, 2010. The Impact National
Benchmark DatabaseTM and the Life Sciences Research
Database, both affiliated with OptumInsight (formerly
Innovus), contain medical and pharmacy claims, and
enrollment information from more than 40 US health plans
with over 14 million and 89 million health plan enrollees,
respectively. Health plans included in these databases were
geographically diverse across the US.
Medical (professional and facility) claims included Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) diagnosis codes, ICD-9-CM pro-
cedure codes, Current Procedural Terminology, Version 4
(CPT-4) procedure codes, Healthcare Common Procedure
Coding System (HCPCS) procedure codes, site of service
codes, and health plan and patient paid amounts. Outpatient
pharmacy claims included national drug codes (NDC) for
dispensed medications, dosage form, fill date, health plan, and
patient paid amounts. All administrative claims data were
de-identified and compliant with the provisions of the Health
Insurance Portability and Accountability Act of 1996.
Study patient identification
Health plan enrollees were included in this analysis if they met
one of the following three criteria to identify patients with
acromegaly: (1) had at least two medical claims separated by
at least 30 days with a primary or secondary acromegaly
diagnosis code (ICD-9-CM: 253.0) between January 1, 2003
and June 30, 2009 (identification period), (2) had at least one
inpatient facility claim with a primary or secondary acro-
megaly diagnosis code and an acromegaly-related procedure
code (‘‘Appendix’’) during the identification period, or (3) had
at least one claim of any type with an acromegaly-related
procedure code followed by at least one medical claim from
any place of service with a primary or secondary acromegaly
diagnosis code during the identification period. The index date
was defined as the date of the earliest claim for an acromegaly-
related diagnosis code, procedure code, or medication (i.e.,
octreotide acetate, octreotide LAR, lanreotide, pegvisomant,
bromocriptine, cabergoline) during the identification period.
In addition to the criteria above, patients had to be
continuously enrolled with medical and pharmacy benefits
for 6 months before the index date (pre-index period) and
until the earliest of: death (as evidenced by hospital dis-
charge claims or Social Security Administration death
records); disenrollment from the health plan; or the end of
the study period on June 30, 2010 (follow-up period).
Patients were assigned to one of four treatment status
cohorts based on evidence of acromegaly-related surgical
procedures (‘‘Appendix’’) and medication use during the
study period: Surgery Only, Surgery ? Meds, Meds Only,
and None. Additionally, patients who received at least one
acromegaly-related medication during the study period
(i.e., patients in the Surgery ? Meds and Meds Only
cohorts) were assigned to one of six subgroups based on the
first claim for an acromegaly-related medication on or after
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the index date. With respect to the two octreotide agents,
octreotide acetate and LAR are considered the short- and
long-acting formulations of the same medication.
Study measures
The primary outcomes included incident cases of acromegaly-
related comorbidities and complications (‘‘Appendix’’) dur-
ing the follow-up period. The selected comorbidities and
complications were derived from a list of acromegaly clinical
features presented in Cordero et al. [11]. Incident cases were
defined by the first occurrence of a claim for a comorbidity or
complication during the follow-up period, given that no
claims for the comorbidity or complication were present prior
to the index date. The time at risk for a comorbidity or com-
plication was calculated in days from the index date up until
the date of the first claim for the comorbidity or complication.
Demographic variables were measured at the start of the
pre-index period and included age, gender, and US census
geographic regions of the health plans. Pre-index clinical
characteristics included the Quan–Charlson comorbidity
score [12]. All-cause death during the follow-up period was
also reported.
Analyses
All study variables were analyzed descriptively by treatment
status cohorts. Categorical variables were summarized with
frequencies and percentages and continuous variables were
summarized with means and standard deviations (SD). Tra-
ditional F- tests were performed to assess cohort differences in
the continuous measures, and depending on the sample size,
either v2-tests or Fisher’s exact tests were performed to assess
cohort differences in the categorical measures.
Counts of acromegaly-related comorbidities and com-
plications during the follow-up period were tabulated by
study cohort. Incidence rates were calculated for each
comorbidity and complication as the number of new cases
divided by the observed person-days at risk (expressed as
per 10,000 person-days). Pairwise cohort comparisons of
each comorbidity and complication were assessed using
unadjusted incidence rate ratios (IRR) and the exact bino-
mial test. All analyses were performed using SAS v9.2
(SAS Institute, Cary, NC, USA). A p value\0.05 was used
to signify statistical significance.
Results
Baseline characteristics
Of the nearly 37 million commercial health plan enrollees
in the databases between January 1, 2003 and June 30,
2009, 54,413 had at least one claim with an acromegaly
diagnosis code, procedure code, or medication; of which
949 met the remaining study inclusion criteria. The date of
the earliest acromegaly claim (i.e., the index date) was
based on a claim with an acromegaly diagnosis code or
procedure code for 94 % of the study patients. For the
remaining 6 %, the index date was based on a claim for an
acromegaly-related medication. However, all study
patients had the required acromegaly diagnosis codes and
procedure codes necessary for study entry some time dur-
ing the follow-up period.
Table 1 displays the baseline demographic and clinical
characteristics of the total study sample and treatment
status cohorts. Of the 949 patients identified with acro-
megaly, 162 (17 %) had evidence of an acromegaly-related
surgical procedure only (Surgery Only cohort), 140 (15 %)
had evidence of an acromegaly-related surgical procedure
and medication (Surgery ? Meds cohort), 123 (13 %) had
evidence of an acromegaly-related medication only (Meds
Only cohort), and 524 (55 %) had no evidence of a surgical
procedure or medication (None cohort) during the follow-
up period. Overall, patients had a mean (SD) age of 42
(18) years and 52 % were male at the time of the earliest
acromegaly claim. Patients in the Surgery Only cohort
were on average older (48 years) than the other study
cohorts. All cohorts were comparable with respect to
gender. The greatest geographic representation overall, and
within each cohort, came from Southern (39 % overall) and
Northeastern (32 % overall) US census regions. The
majority of patients had a Quan–Charlson score \2; the
Surgery Only and Meds Only cohorts had the highest
proportion of patients with a score of 2 or more.
Overall, the average ± SD length of follow-up was
971 ± 655 days, with a maximum of 2,737 days or
7.5 years. The follow-up times for the Surgery ? Meds
(1,096 ± 711 days), Meds only (1,024 ± 743 days), and
None (984 ± 650 days) cohorts were similar (Sur-
gery ? Meds vs. Meds only: p = 0.421; Surgery ? Meds
vs. None: p = 0.074; Meds only ? None: p = 0.579), but
they were all longer compared to the Surgery only cohort
(781 ± 497 days; all p \ 0.001). The overall proportion of
death was small (1 %) and the difference was not statisti-
cally significant across cohorts.
Incidence of acromegaly-related comorbidities
and complications
Table 2 shows the incidence and incidence rate ratios of 23
acromegaly-related comorbidities and complications. The
highest incidence rates overall were for arthropathy/
arthralgia/synovitis (4.5 per 10,000 person-days) and
hypertension (3.9 per 10,000 person-days); followed by
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hypopituitarism (2.3 per 10,000 person-days), osteoarthritis
(2.1 per 10,000 person-days), diabetes (1.9 per 10,000
person-days), colon polyp (1.6 per 10,000 person-days),
myopathy/myalgia and cardiac dysrhythmia/arrhythmia
(both 1.4 per 10,000 person-days), valvular heart disease
and sleep apnea (both 1.3 per 10,000 person-days), and
menstrual abnormality (1.1 per 10,000 person-days).
Among these, the greatest observed differences were
between the treated (Surgery Only, Surgery ? Meds, and
Meds Only) and untreated (None) cohorts.
Compared to the untreated cohort, all three treatment
cohorts had significantly higher incidence rates of hypo-
pituitarism (IRR: 4.1, 2.9, and 2.4, respectively, all
p \ 0.001) and diabetes (IRR: 2.2, 1.8, 2.6, all p \ 0.05).
The Surgery Only cohort had significantly higher rates of
hypertension (IRR: 2.2; p \ 0.001), valvular heart disease
(IRR: 2.2; p \ 0.01), cardiac dysrhythmia/arrhythmia
(IRR: 2.1; p \ 0.01), and sleep apnea (IRR: 2.4; p \ 0.01)
than the None cohort. The Surgery ? Meds cohort had a
significantly higher rate of sleep apnea (IRR: 2.3;
p \ 0.01) and the Meds Only cohort had a significantly
higher rate of valvular heart disease (IRR: 1.8; p \ 0.05)
than the None cohort. The Surgery ? Meds (IRR: 2.4;
p \ 0.001) and Meds Only (IRR: 1.9; p \ 0.01) cohorts
both had significantly higher rates of colon polyps than the
None cohort. However, the reverse was found with
myopathy/myalgia; the Surgery Only (IRR: 0.5; p \ 0.05)
and Surgery ? Meds (IRR: 0.5; p \ 0.05) cohorts had
significantly lower rates of myopathy/myalgia than the
None cohort. Among the treatment cohorts, the Surgery
Only cohort was found to have a significantly higher rate of
hypertension than the Surgery ? Meds cohort (IRR: 1.7;
p \ 0.05).
While the incidence rates of these outcomes were
very low, the Surgery Only cohort had significantly
higher rates of heart failure (IRR: 8.8; p \ 0.05) and
impaired libido/impotence (IRR: 3.8; p \ 0.01) com-
pared to the Surgery ? Meds cohort; the Surgery Only
cohort also had a significantly higher rate of visual
defects than the Meds Only cohort (IRR: 4.3; p \
0.01); while the Surgery ? Meds cohort had a signifi-
cantly higher rate of visual-field defects (IRR: 4.9;
p \ 0.001) but a significantly lower rate of impaired
libido/impotence (IRR: 0.3; p \ 0.05) than the Meds
Only cohort.
Compared to the None cohort, remaining differences
included: the Surgery Only cohort had higher rates of
visual-field defects (IRR: 5.2; p \ 0.001) and carpal tunnel
syndrome (IRR: 3.5; p \ 0.01); the Surgery ? Meds
cohort had lower rates of cardiac hypertrophy (IRR: 0.03;
p \ 0.05) and heart failure (IRR: 0.2; p \ 0.05); and the
Meds Only cohort had a higher rate of carpal tunnel syn-
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Medical therapy subanalysis
Use of an acromegaly-related medication during the follow-
up period is presented in Table 3 for the 263 study patients
in the Surgery ? Meds and Meds Only cohorts. Nearly half
(48.7 %) of the sample had at least one claim for octreotide
acetate during the follow-up period. Other common follow-
up medications included octreotide LAR (45.3 %) and
cabergoline (32.7 %). Use of all medications, except lan-
reotide, did not differ between cohorts. A higher proportion
of patients in the Surgery ? Meds cohort were prescribed
lanreotide compared to patients in the Meds Only cohort
(11.4 vs. 4.1 %; p = 0.028). The mean (SD) time between
the index date and the date for the first medication claim
was 233 (339) days for the Surgery ? Meds cohort and 119
(315) days for the Meds Only cohort.
Table 4 displays the subsequent medications that
patients were prescribed following their first (index) med-
ication. Of the 263 patients with at least one claim for an
acromegaly-related medication during the follow-up per-
iod, 103 (39.2 %) had an index claim for octreotide acetate,
49 (18.6 %) for octreotide LAR, 11 (4.2 %) for lanreotide,
17 (6.5 %) for pegvisomant, 26 (9.9 %) for bromocriptine,
and 57 (21.7 %) for cabergoline.
More than half (52.4 %) of the patients with an index
octreotide acetate claim later filled a prescription for octre-
otide LAR. However, fewer patients added a medication in
the other subgroups during the follow-up period. The most
commonly added medication in each subgroup included:
cabergoline was added by 5 (10.2 %) with an index octreo-
tide LAR and 4 (15.4 %) with an index bromocriptine pre-
scription; pegvisomant was added by 2 (18.2 %) with an
index lanreotide prescription; octreotide acetate was added
by 3 (17.6 %) with an index pegvisomant, 4 (15.4 %) with an
index bromocriptine and 15 (26.3 %) with an index
cabergoline prescription.
Discussion
This retrospective analysis of 949 acromegaly patients was
performed using administrative claims data from two large
health plan databases in the United States. The study eval-
uated the incidence of comorbidities and complications and
the use of acromegaly-related medications among acro-
megaly patients. Differences in these clinical outcomes were
examined across treatment status cohorts. The results
establish that for nearly half of all comorbidities and com-
plications considered, the incidence was low (\1 per 10,000
person-days) and/or did not differ across treatment status
cohorts. However, a number of major comorbidities were
identified with higher frequency (C1 per 10,000 person-
days) such as arthropathy, hypertension, hypopituitarism,













Octreotide acetate 128 (48.7) 74 (52.9) 54 (43.9) 0.147
Octreotide LAR 119 (45.3) 66 (47.1) 53 (43.1) 0.510
Lanreotide 21 (8.0) 16 (11.4) 5 (4.1) 0.028
Pegvisomant 45 (17.1) 27 (19.3) 18 (14.6) 0.318
Bromocriptine 32 (12.2) 13 (9.3) 19 (15.4) 0.127




179 (332) 233 (339) 119 (315) 0.005
Table 4 Subsequent medication use following index acromegaly-related medication













Octreotide acetate (ACE) – 3 (6.1) 0 (0.0) 3 (17.6) 4 (15.4) 15 (26.3)
Octreotide LAR 54 (52.4) – 1 (9.1) 3 (17.6) 1 (3.8) 11 (19.3)
Lanreotide 3 (2.9) 4 (8.2) – 0 (0.0) 0 (0.0) 3 (5.3)
Pegvisomant 17 (16.5) 3 (6.1) 2 (18.2) – 1 (3.8) 5 (8.8)
Bromocriptine 4 (3.9) 1 (2.0) 0 (0.0) 0 (0.0) – 1 (1.8)
Cabergoline 17 (16.5) 5 (10.2) 1 (9.1) 2 (11.8) 4 (15.4) –
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included: colon polyps, myopathy/myalgia, cardiac dys-
rhythmia/arrhythmia, valvular heart disease, sleep apnea,
and menstrual abnormality. Also, patients receiving treat-
ment had a higher incidence of comorbidities and compli-
cations compared to patients without treatment. Myopathy
was the only high frequency condition where patients with
treatment had a lower incidence than patients without
treatment (IRR: 0.5; p \ 0.05 for both Surgery Only and
Surgery ? Meds cohorts compared to the None cohort). The
acromegaly patients in the current study shared many of the
same clinical features of acromegaly patients studied in other
clinical settings. Although the types of morbidity were
similar, the observed prevalences were often lower than the
ranges of morbidity reported elsewhere [2, 6, 7, 10, 11, 13].
For example, Davi’ et al. [14] reported that the prevalence of
sleep apnea syndrome was 47 % and ranged from 39 to 56 %
for patients with controlled and uncontrolled disease. At
most, the prevalence in our population was 29.6 % (48/162)
for patients in the surgery only cohort. Different study
designs and/or coding errors in the claims may explain the
varying prevalence estimates in the different studies.
As with all studies relying on retrospective administrative
claims data, there are limits to how well claims can capture
an individual’s medical history. Claims data are collected for
the purpose of payment. As a result, the presence or absence
of a diagnosis code on a medical claim does not confirm or
deny actual disease. Likewise, procedure codes may be
missing from inpatient claims, thus the data related to sur-
geries and other inpatient procedures may be incomplete.
A similar limitation also applies to claims for prescribed
medications. Presence of a claim for a dispensed medica-
tion does not guarantee that the medication was taken and
taken as prescribed. Additionally, patients could have
received medication samples from the physician’s office,
filled a prescription outside the health care pharmacy sys-
tem, or received medication during a clinical trial, all of
which are not captured in the claims. As a result, cohort
and subgroup assignments may not correctly reflect
patients’ actual treatment experiences.
Although the treatment status cohorts may be limited by
coding errors and missing clinical information in the claims,
they are measures of treated and untreated disease during the
study’s observation period and may be viewed as an available
proxy of active disease status. Unfortunately, disease control,
which may be viewed as more clinically relevant, does not
have an available proxy in the claims. In this managed care
population, 55 % of patients without treatment had a signifi-
cantly lower incidence of most major comorbidities than
patients with treatment, including hypertension, diabetes,
valvular heart disease, and cardiac arrhythmias. The lower
incidence of comorbidities and complications among patients
with no treatment may have resulted from patients receiving a
surgical cure or entering remission prior to the observation
period. While the higher incidence of comorbidities and
complications among patients with treatment may have
resulted, in part, from some patients obtaining inadequate
disease management and/or poor disease control.
Of the 28 % of patients with evidence of an acromegaly-
related medication, a greater proportion of patients had
claims for octreotide, cabergoline, and bromocriptine than
lanreotide and pegvisomant. Pegvisomant is a newer GH
antagonist that requires daily injection. It is indicated as a
second-line treatment in evolutive acromegaly and
administered to patients showing resistance to octreotide
[1, 15]. Although expensive, for some patients with overly
active acromegaly, it is the only way to control the disease
[16].
The use of cabergoline and bromocriptine as a primary
choice during the study period of 2002 through 2010 is likely
due to their oral, rather than injectable, formulations. How-
ever, bromocriptine, even at high doses, is less efficacious
than cabergoline, and cabergoline monotherapy is only
efficacious in reducing serum GH below 2 lg/L in about
30 % of patients [17]. Comparatively, the efficacy of peg-
visomant ranged from about 75 to 97 %, octreotide from
about 65 to 79 %, and lanreotide from about 50 to 76 % for a
variety of efficacy measures including, but not limited to,
reducing serum GH, normalizing IGF-1, and reducing tumor
size. As for octreotide acetate and octreotide LAR, studies
have reported that the efficacies of the two formulations are
similar. More than half (52 %) of patients in the octreotide
acetate subgroup started octreotide LAR sometime during
the follow-up period, which is consistent with current
treatment guidelines. Current research on the long-term
health risks of these medications in acromegaly patients is
limited. A lack of familiarity with these issues by non-spe-
cialized clinicians may also help explain this finding. Future
research substantiating the level of risk is recommended.
In addition to the limitations described above, additional
limitations must be considered when interpreting the study
results. First, the data used for this study came from a
managed care population and may not be generalizable to
other health plan populations. The plans used for analysis,
however, are discounted fee-for-service, IPA-network
plans and not capitated or gatekeeper models. Therefore,
the results from this study are primarily applicable to
populations which receive their care through similar
delivery systems. The plans used for analysis included a
wide geographic distribution across the United States, and
therefore provide the capability for generalization to
comparable managed care populations on a national level.
Second, the inherent challenges of studying acromegaly
in an administrative claims database included limited
availability of clinical information and laboratory results
needed to accurately identify patients with acromegaly,
examine the use of treatment monitoring, determine the
360 Pituitary (2013) 16:354–362
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current disease status as active or inactive, and assess
whether the treated disease was controlled or uncontrolled.
Third, despite the large denominator and multiple study
years in the underlying databases, sample sizes in some
table cells were small, which limited the opportunity to
match or adjust for patient differences in a consistent
manner across key outcomes.
Acromegaly is challenging to diagnose and there are no
means for accurately identifying patients with acromegaly
in claims data alone; however, the inclusion of a retro-
spective chart review may be an option for validating the
disease status, progression, and clinical outcomes observed
in the present study.
In the course of this claims study, substantial emphasis
was placed on multiple pathways to case identification.
However, no medical chart abstraction was conducted to
validate accurate case definition. The observation that 55 %
of acromegaly patients had no evidence of acromegaly
treatment was an unexpected finding. With the exception of
the small proportion of patients for whom surgery is cura-
tive, we expected that more patients would have received
pharmacological treatment for acromegaly. Future research
should include a medical chart review to validate the patient
identification algorithm used in this claims database study
and to further study real-world comorbidities and treatment
patterns in patients with acromegaly.
Conclusions
This study examined the real-world comorbidities and treat-
ment of 949 acromegaly patients in two large US administra-
tive claims databases. In this study, patients with acromegaly
were found to have a high level of serious comorbidities
(hypertension, diabetes, valvular heart disease, and cardiac
dysrhythmia/arrhythmia). The incidence of comorbidities was
highest among patients with acromegaly-related treatment,
which may have resulted, in part, from inadequate disease
management and/or poor disease control. In addition, over half
of the patients received no treatment for acromegaly (neither
surgery nor medication) and only 28 % received an acro-
megaly-related medication during the study period. Given that
cure rates with surgery alone are relatively low for macroad-
enomas, the most common source of GH excess, a greater use
of medical therapy was expected. However, some patients may
have received a curative surgery prior to the observation per-
iod, which may have reduced the use of other acromegaly-
related treatments during the study period.
Additional research, including medical chart review and
collection of data on GH and IGF-1 laboratory results, is
warranted to further understand the factors associated with
diagnosis and the potential under-treatment of patients
with acromegaly. Furthermore, knowing the many clinical
features of acromegaly and the side effects of its treatment
may facilitate earlier diagnosis and treatment, and appro-
priate follow-up care, which may avoid or at least mini-
mize the life-long consequences of uncontrolled disease.
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CPT 61546 Craniotomy for hypophysectomy or excision of
pituitary tumor, intracranial approach
61548 Hypophysectomy or excision of pituitary tumor,
transnasal or transseptal approach, nonstereotactic
62165 Neuroendoscopy, intracranial; with excision of
pituitary tumor, transnasal or trans-sphenoidal
approach
77371 Radiation treatment delivery, stereotactic radiosurgery
(SRS), complete course of treatment of cranial
lesion(s) consisting of 1 session; multi-source Cobalt
60 based
77372 Radiation treatment delivery, stereotactic radiosurgery
(SRS), complete course of treatment of cranial
lesion(s) consisting of 1 session; linear accelerator
based
77432 Stereotactic radiation treatment management of cranial




07.61 Partial excision of pituitary gland, transfrontal
approach
07.62 Partial excision of pituitary gland, transsphenoidal
approach
07.63 Partial excision of pituitary gland, unspecified
approach
07.64 Total excision of pituitary gland, transfrontal approach
07.65 Total excision of pituitary gland, transsphenoidal
approach
07.68 Total excision of pituitary gland, other specified
approach
07.69 Total excision of pituitary gland, unspecified approach
92.30 Stereotactic radiosurgery, not otherwise specified
92.39 Stereotactic radiosurgery, not elsewhere classified
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Arthropathy/arthralgia/synovitis 713.x, 716.4x–716.5x, 716.8x–
716.9x, 719.4x, 727.0x
Kyphosis and scoliosis 737.1x, 737.3x–737.9
Vertebral fracture 733.13, 805.xx–806.xx





























Menstrual abnormality 626.x, 627.0–627.1




Modified from Cordero et al. [11]
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